HBV-DNA检测及血液细胞分析在肝炎性肝硬化治疗效果评价中应用  

Application of HBV-DNA Detection and Blood Cell Analysis in the Evaluation of the Therapeutic Effect of Hepatitis Cirrhosis

作　　者：王华[1] 牛琰[1] 赵瑞敏[2] 宋予娟[1] Wang Hua;Niu Yan;Zhao Rui-min;Song Yu-juan(Department of Medical Laboratory,First People's Hospital of Xinxiang City,Xinxiang 453000,Henan Province,China;Department of Gastroenterology,First People's Hospital of Xinxiang City,Xinxiang 453000,Henan Province,China)

机构地区：[1]河南省新乡市第一人民医院医学检验科,河南新乡453000 [2]河南省新乡市第一人民医院消化科,河南新乡453000

出　　处：《罕少疾病杂志》2023年第8期53-54,共2页Journal of Rare and Uncommon Diseases

摘　　要：目的探讨与分析HBV-DNA检测及血液细胞分析在肝炎性肝硬化治疗效果评价中应用价值,以促进早期预测患者的预后。方法2019年2月到2022年1月选择在本院诊治的肝炎性肝硬化患者137例作为研究对象,所有患者都给予恩替卡韦治疗,在治疗前进行HBV-DNA检测及血液细胞分析,观察患者的预后并进行相关性分析。结果所有患者治疗观察3个月,有效患者数为107例,治疗有效率为78.1%。有效患者的性别、年龄、体重指数、病程、肝功能分级、血压等与无效患者对比无明显差异(P>0.05)。有效组的红细胞、血小板、白细胞、血红蛋白等血液细胞分析指标都明显高于无效组(P<0.05)。有效组的HBV-DNA载量明显少于无效组(P<0.05),血清TBi L、DBi L、ALP、GGT含量明显低于无效组(P<0.05)。在137例患者中,Spearsman分析显示红细胞、血小板、白细胞、血红蛋白、HBV-DNA载量都与患者预后有效呈现相关性(P<0.05)。结论恩替卡韦治疗乙肝肝硬化患者的疗效有待提高,HBV-DNA检测及血液细胞分析在肝炎性肝硬化治疗中的应用能有效评估患者预后情况。Objective To explore and analysis the application values of HBV-DNA detection and blood cell analysis in the evaluation of the treatment effects of hepatitis cirrhosis,so as to promote the early prediction of the prognosis of patients.Methods From February 2019 to January 2022,137 cases of patients with hepatitis cirrhosis who were diagnosed and treated in our hospital were selected as the research subjects.All patients were treated with entecavir.HBV-DNA detection and blood cell analysis were performed before treatment,and the patients’prognosis were observed and given correlation analysis.Results All patients were observed for 3 months,there were 107 cases were effective,and the effective rate were 78.1%.There were no significant difference in gender,age,body mass index,course of disease,liver function classification,blood pressure,etc.Compared between the effective patients and the ineffective patients(P>0.05).The red blood cells,platelets,white blood cells,hemoglobin and other blood cell analysis indexes in the effective group were significantly higher than those in the ineffective group(P<0.05).The HBVDNA load in the effective group were significantly lower than that in the ineffective group(P<0.05),and the serum levels of TBiL,DBiL,ALP and GGT were significantly lower than those in the ineffective group(P<0.05).In the 137 patients,Spearsman analysis showed that red blood cells,platelets,white blood cells,hemoglobin,and HBV-DNA loads were effectively correlated with patient prognosis(P<0.05).Conclusion The efficacy of entecavir in the treatment of patients with hepatitis B cirrhosis needs to be improved.The application of HBV-DNA detection and blood cell analysis in the treatment of hepatitis B cirrhosis can effectively evaluate the prognosis of patients.

关 键 词：恩替卡韦 乙肝肝硬化 HBV-DNA 血液细胞分析 肝炎性肝硬化 

分 类 号：R657.31[医药卫生—外科学]